Thursday, July 29

BioNTech offers 10 times more antibodies than Sinovac | Digital Trends Spanish

A study carried out by the University of Hong Kong reveals that those who received the Pfizer-BioNTech coronavirus vaccine have ten times more antibodies than those who were inoculated with Sinovac.

The work also shows that the latter group generates levels of proteins to attack the virus that would be similar or lower than those produced naturally in patients who have recovered from COVID-19.

According to the researchers, the study results, which were published in Lancet Microbe, suggest the need for “alternative strategies”, such as booster vaccines, for those who have been immunized with Sinovac, as a way to increase antibody levels in these patients.

“The difference in neutralizing antibody concentrations identified in our study could translate into substantial differences in the efficacy of the vaccine,” the research notes.

The Chilean case

Just yesterday, the vaccine produced by the Chinese pharmaceutical company received an important boost from a study carried out by the Ministry of Health, the Ministry of Sciences and the Catholic University of Chile.

The work, carried out on 2,300 people, shows that the vaccine has very good protection against severe cases and death from this disease.

In accordance with an article published in La Tercera As a result of the results, the vaccine “develops antibodies capable of blocking the entry of the virus into the cells (neutralizing antibodies against the Spike or S protein), but these diminish over time so a dose of booster vaccine is necessary that allows to increase this protection ”.

According to the Chilean study, of the 2,300 vaccinated, only 45 have been infected with COVID-19 and most of them mildly.

Meanwhile, only three have required hospital care and none have died.

Editor’s Recommendations

var stage = decodeURIComponent(0); var options = JSON.parse(decodeURIComponent('')); var allOptions = {};

if (stage > 0 && window.DTOptions) { allOptions = window.DTOptions.getAll();

Object.keys(options).forEach(function(groupK) { if (options[groupK] && typeof options[groupK] === 'object') { Object.keys(options[groupK]).forEach(function(k) { if (!allOptions[groupK] || typeof allOptions[groupK] !== 'object') { allOptions[groupK] = {}; }

allOptions[groupK][k] = options[groupK][k]; }); } }); } else { allOptions = options; }

var getAll = function () { return allOptions; };

var get = function (key, group, def) { key = key || ''; group = group || decodeURIComponent('qnqb92BhrzmkpqGx'); def = (typeof def !== 'undefined') ? def : null;

if (typeof allOptions[group] !== 'undefined') { if (key && typeof allOptions[group][key] !== 'undefined') { return allOptions[group][key]; } }

return def; };

var set = function (key, group, data) { key = key || ''; group = group || decodeURIComponent('qnqb92BhrzmkpqGx'); data = data || null;

if (key) { if (typeof allOptions[group] === 'undefined') { allOptions[group] = {}; }

allOptions[group][key] = data; } };

var del = function (key, group) { key = key || ''; group = group || decodeURIComponent('qnqb92BhrzmkpqGx');

if (typeof allOptions[group] !== 'undefined') { if (key && typeof allOptions[group][key] !== 'undefined') { allOptions[group][key] = null; } } };

window.DTOptions = { get: get, getAll: getAll, set: set, del: del, }; }());

Leave a Reply

Your email address will not be published. Required fields are marked *